Review of Benefits of Radiotracer in Bone Metastases

Running Head: REVIEW OF THE BENEFIT OF RADIOTRACER IN BONE METASTASES
REVIEW OF THE BENEFIT OF RADIOTRACER IN BONE METASTASES
Name of the Student:
Name of the University:
Author Note:

1REVIEW OF THE BENEFIT OF RADIOTRACER IN BONE METASTASES
Abstract:
Introduction:
The early detection of the skeletal metastasis is very important and necessary for the
optimal treatment and accurate staging of the stage of cancer. Wilms tumor is considered as the
second most common pediatric solid tumor and is found to be one of the most common renal
tumour found in the infants and young children (Uslu et al, 2015). The role of imaging is one of
the primary ways to evaluate plan the intervention for a metastatic disease. The majority of the
renal tumours arises from the mesodermal precursors of the renal parenchyma, which are also
known as metaphors and are responsible for the cause of atleast 90 % of the paediatric renal
tumours.
Purpose:
Skeletal scintigraphy (Davila, Antoniou and Chaudhry, 2015) assists in diagnosing and
testing a range of skeleton diseases and disorders using tiny amounts of radioactive isotopes
called radiotracers that are inserted into the bloodstream. The radiotracer passes via the area
getting investigated and delivers radiation in the range of gamma rays and a special gamma
camera and a device is kept to track and create images of ones's bones. As it can detect molecular
movement within the body, skeletal scintigraphy provides the ability in its earliest stages to
recognize pathology. The paper below discusses and reviews the benefit of using a radiotracer,
which helps in the better and swift detection of bone metastases in renal carcinomas occurring in
the children.

2REVIEW OF THE BENEFIT OF RADIOTRACER IN BONE METASTASES
Methodology:
Positron emission tomography (PET) has developed among the most effective scanning
modalities for staging, re-staging, identifying reoccurrence and/or metastasis and tracking
therapeutic action in most malignant diseases. Most widely utilized in PET imaging is 18F-
fluoro-2-deoxy-2-d-glucose (FDG), a non-radiotracer with a chemical composition close to that
of naturally occurring glucose. FDG reaches the cells via the same glucose-membrane proteins
used by alcohol, usually overexpressed in cancer cells. FDG imaging (Takahashi et al, 2015)
depends on Warburg's finding that enhanced glycolysis of adenosine triphosphate is needed to
meet the metabolic requirements of progressively dividing tumor cells. Membrane glucose
transporters, primarily GLUT-1, successfully transmit FDG to the cell where hexokinase
transforms it to FDG-6-phosphate. As FDG-6-phosphate is not a medium for further measures in
glycolysis, it is stuck in the cell and builds up the glucose metabolic activity significantly.
Metabolic quantitation by measuring SUV on FDG PET / CT may play a significant role in
assessing lesion biological activity and predicting the prognosis of patients. A total of 60 tests
were conducted in patients with bone metastases in renal carcinoma using 18F-FDG-PET / CT
within a five-year span. Such patients were 15 baby boys and 15 baby girls aged 6 months to 12
years of age were found either a conservative approach to treatment or progressive surgery. A
longitudinal review of the prospectively collected data was carried out about the therapeutic
approach choice and the patients ' future fate. From the judgment regarding the type of treatment
the patients were tracked for at least 12 months. Mortality was tracked across the entire group,
conservatively handled in subsets of surgically treated babies and the patients. The study of the
relationship between the average 18F-FDG accumulation and survival was undertaken, as well as
the correlation between the 18F-FDG deposition amount and the histological tumor rating.